Novo Nordisk’s 2025 price change for Ozempic and Wegovy is a notable shift in GLP‑1 access: the company lowered certain retail prices so a cash-pay semaglutide option is now within reach for more people.
Recent federal agreements have transformed the pricing landscape for GLP-1 and GIP weight-loss medications, opening up new avenues of affordability for Austin patients who previously faced financial barriers.
In Austin’s vibrant health-conscious community, many people are turning to medical weight-loss treatments for support. Unfortunately, some clinics and online sellers are offering compounded Semaglutide and Tirzepatide as cheaper alternatives.
